Kimberly-Clark to buy Tylenol maker Kenvue, Iren & Microsoft deal

There are a number of stocks on the move on Monday, Nov. 3. Kimberly-Clark (KMB) announced it is buying Kenvue (KVUE) in a deal valued at $48.7 billion. Iren (IREN) shares are soaring after striking a $9.7 billion deal with Microsoft (MSFT). Pfizer (PFE) is suing to block Novo Nordisk's (NVO) bid for obesity startup Metsera (MTSR).

To watch more expert insights and analysis on the latest market action, check out more Morning Brief.

Video Transcript

00:00 Speaker A

We are watching Kimberly-Clark, Iron, and Pfizer. First up Kimberly-Clark, the consumer giant will purchase Tylenol maker Kenvue for 40 billion. Kimberly-Clark says the combination will allow it to surpass Unilever to become the second biggest seller of health and wellness products. In addition to Tylenol, Kenvue's portfolio includes Neutrogena, Listerine, Benadryl and more. Kimberly-Clark's brands for its part include Kleenex and Cottonelle Cottonelle toilet paper. Uh so we'll be watching those companies

00:33 Speaker A

closely. Next up we got Iron. It's striking a 9.7 billion dollar deal with Microsoft. The tech giant will purchase AI cloud capacity from the Australian data center company and become its largest customer. Now, Iron's based in Australia, but has a number of data centers in the US and it's a so-called neo cloud company, which operates data centers that specialize in AI. Its shares already up more than 500% this year. And finally Pfizer, it's suing to block Novo Nordisk's bid for obesity startup Metsira.

01:03 Speaker A

Pfizer initially filed a lawsuit on Friday to halt the competing bid, and it has filed a second lawsuit today. The company's accusing Novo of using its proposed acquisition of Metsira to stifle competition in the GLP-1 drug market. But the clock's ticking for Pfizer. Unless the court grants the restraining order, the company has until tomorrow to offer a counter bid for Metsira or walk away from that deal. As always, you can scan the QR code below to track the best and worst performing stocks with Yahoo Finance's trending tickers page.

View Comments